T
Terran Biosciences
Transforming the lives of patients with neurological and psychiatric illnesses
About Terran Biosciences
A biotech platform company with a focus on developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.
Terran Biosciences is building a CNS-focused, tech-enabled drug development platform and is rapidly advancing a number of assets that include late-stage therapeutics for schizophrenia, Alzheimer's, and Parkinson's disease. The company's business model is centered on research and development of novel drugs and technologies, with the goal of commercializing them through licensing or direct sales after regulatory approval. Its target market is the global pharmaceutical and biotech industry for central nervous system disorders, and its clients are patients suffering from these conditions.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Miami, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
Presight Capital
ImpactAssets
PsyMed Ventures
Astir Ventures
Magna Filis
Valhalla Ventures
Noetic Fund
Redbeard Ventures
YADAY
Tabularasa Ventures
Transhuman Capital
Deep End Partners
The Brkfst Club
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Terran Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Terran Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.